TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02373280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)
Description: In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)
Description: the participants received PPI based triple therapy\[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]
Description: moxifloxacin triple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)
Description: bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\], bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)\] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
Study: NCT00909311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: capsules, QD, 1 dose in each cross-over period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: capsules, QD, 1 dose in each cross-over period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: capsule, QD, 1 dose in each cross-over period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: capsule, QD, 1 dose in each cross-over period
Study: NCT00328770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
Study: NCT02741102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
Study: NCT02467933

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo letter
Description: The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial Informative letter
Description: The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Followup Informative Letter
Description: The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
Study: NCT03239717

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whey protein powder
Description: Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCAD2
Description: Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
Study: NCT01571583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day \[5 to 6 tablets\] based on subject weight), twice daily regimen, for 48 weeks.
Study: NCT04561154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology
Study: NCT04830670

Intervention type: PROCEDURE
Intervention: sinus floor elevation with lateral approach
Description: sinus floor elevation with lateral approach. 6 months healing phase. implant site preparation with trephine bur and bone specimen retrieval.

Intervention type: PROCEDURE
Intervention: sinus floor elevation with lateral approach
Description: sinus floor elevation with lateral approach. 6 months healing phase. implant site preparation with trephine bur and bone specimen retrieval.
Study: NCT02433600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk-based infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow milk-based infant formula with enriched protein fractions
Study: NCT03865693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scarmbler therapy
Description: Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: scarmbler therapy
Description: Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
Study: NCT00291447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch806
Description: ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch806
Description: ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch806
Description: ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch806
Description: ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.
Study: NCT00453271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB-002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB-002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB-002

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vehicle control
Study: NCT02488395

Intervention type: OTHER
Intervention: fMRI
Description: The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).

Intervention type: OTHER
Intervention: fMRI
Description: The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).

Intervention type: OTHER
Intervention: Ophthalmologic evaluation
Description: The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.

Intervention type: OTHER
Intervention: Ophthalmologic evaluation
Description: The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.

Intervention type: OTHER
Intervention: visual psychophysics test
Description: This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.

Intervention type: OTHER
Intervention: visual psychophysics test
Description: This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
Study: NCT03473431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: single infusion of 0.5 mg / kg ketamine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
Study: NCT04293770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect adhesive restoration of posterior teeth
Description: Indirect restoration of significant loss of dental hard tissue
Study: NCT01246791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-01
Description: NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
Study: NCT03936374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Participants will receive BMS-986205 on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Participants will receive omeprazole on Days 10 to 15
Study: NCT02956382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is dispensed as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is dispensed as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is dispensed as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is dispensed as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is dispensed as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is dispensed as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is dispensed as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is dispensed as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is dispensed as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is dispensed as a tablet.
Study: NCT05892809

Intervention type: OTHER
Group type: OTHER
Intervention: use an incubator cover
Description: Vital signs of term and preterm newborns were measured separately and with and without an incubator cover.
Study: NCT01793415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IodoCarb (r)
Description: Powder, 3 grams daily for 28+-2 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-iodinated activated charcoal 3 g daily for 28+-2 days
Study: NCT02407678

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-mediated REP1 gene replacement
Description: AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
Study: NCT02597621

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01521273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean varieties
Description: 10 x 50 g/ arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean varieties
Description: 10 x 50 g/ arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean varieties
Description: 10 x 50 g/ arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean varieties
Description: 10 x 50 g/ arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean varieties
Description: 10 x 50 g/ arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean varieties
Description: 10 x 50 g/ arm
Study: NCT04453579

Intervention type: BEHAVIORAL
Intervention: Telephonic interview during the Italian lockdown.
Description: The interview was composed of socio-demographic items lockdown, and dichotomous questions about physical and mental health in relation to the COVID-19 emergency
Study: NCT02020486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 2 mg up to 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 2 mg up to 6 mg
Study: NCT01747057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic-parameters-guided fluid management
Description: ● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation\* and with sinus rhythm.~1. PPV \>12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ \[(PPmax+PPmin)/2\] x100 (during 5 respiratory cycles)~2. SVV \> 12% (15). SVV: Stroke volume variation~   * A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.~Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV \< 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP\>12).~● Non-preload responsive patients (defined as PPV or SVV \< 12%) will resume the same protocol as responders when fluid response parameters are negative.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-guided-fluid management
Description: Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (\> 65mmHg) or CVP \> 12mmHg. If CVP reaches \> 12 mmHg and MAP remains \< 65mmHg, norepinephrine should be started to reach MAP \> 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output \< 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC\>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
Study: NCT01726946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-135
Description: 12 weeks of VX-135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-135
Description: 12 weeks of VX-135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 12 weeks of ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 12 weeks of ribavirin
Study: NCT03650998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: See arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: See arm description
Study: NCT04067947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG005
Description: XG005 Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Tablet
Study: NCT02064387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2857916
Description: A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2857916
Description: A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2857916
Description: A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2857916
Description: A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
Study: NCT03553823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Description: At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
Study: NCT03097900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate
Description: 25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
Study: NCT04568408

Intervention type: DEVICE
Intervention: Xiaomi MiBand 5
Description: Comparison of sleep-monitoring device against polysomnography (PSG)
Study: NCT00794560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient education
Description: Possible, individualized interventions:~* Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~* Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~* Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~* First self-injection under control of a specially trained pharmacist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient education
Description: Possible, individualized interventions:~* Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~* Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~* Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~* First self-injection under control of a specially trained pharmacist
Study: NCT01665963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TopClosure(c) System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Bandage
Study: NCT03161756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
Study: NCT03413930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision
Description: Patients undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic total mesorectal excision
Description: Patients undergo Laparoscopic total mesorectal excision.
Study: NCT02239263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 6 Sound Processor